PGEN — PRECIGEN, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1356090 ·
Last close
$5.32
Market Cap
$1.90B
52W High
$6.04
52W Low
$3.51
ADV30
5,686,165
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 23,252,000 | 20,693,000 | -5,994,000 | -7,929,000 | 138,627,000 | 7,480,000 | 118,392,000 |
| Dec 2025 | 4,565,000 | 2,969,000 | -21,666,000 | -23,503,000 | 155,505,000 | 30,234,000 | 134,594,000 |
| Sep 2025 | 2,922,000 | 1,887,000 | -34,481,000 | -146,344,000 | 171,264,000 | 14,322,000 | 129,396,000 |
| Jun 2025 | 856,000 | -236,000 | -27,857,000 | -26,642,000 | 101,896,000 | 13,760,000 | 138,675,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-115,333,000
Investing CF
$25,889,000
Financing CF
$90,836,000
CapEx
$-1,631,000
Dividends Paid
—
Buybacks
$-1,841,000
EPS Diluted TTM
$-1.35
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,349,277,000
Inventory
$14,725,000
Receivables
$26,705,000
ST Investments
$48,766,000
EBIT TTM
$-197,641,000
Pretax Income TTM
$-204,415,000
Interest Exp TTM
$6,774,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$31,595,000
EBITDA
$-86,329,000
Free Cash Flow
$-90,111,504
Enterprise Value
$2,013,509,760
Total Cash
$56,246,000
Total Debt
$98,250,000
Shares Out
356,510,980
Trailing EPS
$-1.21
Book Value
$0.06
ROE
-1145.4%
ROA
-42.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,684,000 | -106,600,000 | -250,642,000 | 155,505,000 | 134,594,000 | — | -87,831,000 |
| Dec 2024 | 3,925,000 | -94,705,000 | -126,235,000 | 145,266,000 | 106,753,000 | — | -68,173,000 |
| Dec 2023 | 6,225,000 | -88,923,000 | -95,904,000 | 151,043,000 | 32,545,000 | — | -66,930,000 |
| Dec 2022 | 26,909,000 | -74,606,000 | 28,317,000 | 215,977,000 | 89,718,000 | — | -65,045,000 |
TTM Snapshot
Revenues TTM
$3,333,000
NetIncome TTM
$13,842,000
OpCashFlow TTM
$0
Assets (Latest)
$145,266,000
Forward EPS
$-0.22
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | $1.90B | $28.91 | — |
| ATAI | AtaiBeckley Inc. | $1.90B | $5.17 | — |
| ZYME | Zymeworks Inc. | $1.89B | $25.88 | — |
| HCM | HUTCHMED (China) Ltd | $1.90B | $11.07 | — |
| URGN | UroGen Pharma Ltd. | $1.88B | $38.56 | — |
News headlines (Yahoo Finance, 1h cache)
Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason
2026-06-23 01:38 · Yahoo
Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS
2026-06-20 17:28 · Yahoo
H.C. Wainwright Remains a Buy on Precigen (PGEN)
2026-06-16 18:45 · Yahoo
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
2026-06-15 10:40 · Yahoo
Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate
2026-06-14 16:11 · Yahoo
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
2026-06-12 20:05 · Yahoo
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
2026-06-11 12:00 · Yahoo
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
2026-06-01 16:00 · Yahoo
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
2026-05-30 18:30 · Yahoo
Spotlight On 3 Growth Companies With Strong Insider Stakes
2026-05-26 17:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.